Key Points bioAffinity Technologies regained compliance with Nasdaq’s minimum bid-price and warrants listing requirements. Nasdaq cancelled the company’s previously scheduled hearing before the Nasdaq Hearings…
September 09, 2026
Actuate Reports Preclinical Synergy for Elraglusib With RAS Inhibitors in Pancreatic Cancer
Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested…
September 09, 2026
Kazia Doses First Patient in Phase 2 Paxalisib Trial for Recurrent AT/RT Brain Cancer
Key Points Kazia Therapeutics dosed the first patient in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent or progressive AT/RT. The study…
September 09, 2026
Dyne Falls on a Rival’s Failed Trial as Analysts Split Sharply Over Whether the Read-Through Holds
Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage company developing therapies for genetically driven neuromuscular diseases, was downgraded by J.P. Morgan on September 9, 2026 to…
September 09, 2026
PRISM Mid-Day Movers: Pharmaceuticals and Biotech are Today’s Leaders.
Opus Genetics, Inc. (NASDAQ: IRD) surged, up 26.5% to $5.49 today, rebounding sharply from yesterday’s $4.34 close. The stock opened at $5.33 and climbed as…
Key Points Opus Genetics reported positive early data from five patients treated with OPGx-BEST1 in a Phase 1/2 study of inherited BEST1-related retinal diseases. All…
Key Points Serina Therapeutics advanced its SER-252 Phase 1b study to Cohort 2 after an independent safety committee reviewed blinded data from the first patient…
September 08, 2026
PDS Biotech Raises Up to $22.55 Million to Advance Cancer Drug Programs
Key Points PDS Biotechnology announced a PIPE financing of up to $22.55 million led by Nant Capital. The company expects an initial $11.55 million closing…
September 08, 2026
Compass Pathways Launches TRD Education Campaign at Psych Congress 2026
Key Points Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans. The campaign focuses…
September 08, 2026
BrainsWay Pilot Study Links Deep TMS to Depression Improvement in Early Alzheimer’s Patients
Key Points BrainsWay reported results from a 12-patient pilot study of Deep TMS in people with major depressive disorder and early-stage Alzheimer’s disease. After 36…
Quoin Pharmaceuticals (NASDAQ: QNRX) announced on September 8 that the FDA granted Rare Pediatric Disease Designation to QRX003 for the treatment of Peeling Skin Syndrome….
Key Points The FDA granted Breakthrough Therapy designation to Definium Therapeutics’ DT120 orally disintegrating tablet for major depressive disorder. The designation follows positive Phase 3…